Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, but don’t call it a failureBy Mario Cazombo / November 24, 2025 Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against Alzheimer’s.
Book Review: The Financial Restructuring Tool Set August 6, 2025 / Book Reviews, Corporate Finance, Drivers of Value, Economics, Financial Statement Analysis, General
